Sign In
Buy DYN
$17.99
+0.750 (+4.35%)
At Close: Jun 03, 2026
Dyne Therapeutics, Inc. (DYN) Discusses Positive Topline Results From DELIVER Registrational Expansion Cohort in Duchenne Muscular Dystrophy Transcript
Dyne's Duchenne Drug Shows Strong Muscle And Function Improvements
01:37pm, Monday, 08'th Dec 2025
Dyne Therapeutics reported positive results from Phase 1/2 DELIVER trial for z-rostudirsen in DMD amenable to exon 51 skipping.
- Registrational Expansion Cohort (REC) met primary endpoint, demonstrating statistically significant increase in dystrophin to 5.46% at 6 months (muscle content-adjusted; p
WALTHAM, Mass., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive
Dyne Therapeutics Stock Down 30% in a Year — So Why Did One Investor Add Nearly 1 Million Shares?
03:21pm, Wednesday, 03'rd Dec 2025
California-based Palo Alto Investors acquired 997,698 DYN shares in the third quarter. Overall, the position value increased by $13.5 million from quarter to quarter.
Why Dyne Therapeutics Stock Was Crushing it This Week
03:43pm, Friday, 21'st Nov 2025
It was mentioned positively in a new analyst note on the biotech sector. The researchers feel a recent rally in such titles somewhat unfairly left it behind.
Arcadia Investment Management Corp MI Raises Stake in Dyne Therapeutics, Inc. $DYN
04:12am, Saturday, 15'th Nov 2025
Arcadia Investment Management Corp MI increased its position in Dyne Therapeutics, Inc. (NASDAQ: DYN) by 23.1% in the second quarter, according to the company in its most recent Form 13F filing with t
Dyne Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business Highlights
04:10pm, Wednesday, 05'th Nov 2025
- Topline data from Registrational Expansion Cohort of DELIVER trial of zeleciment rostudirsen (z-rostudirsen, also known as DYNE-251) in DMD on track for December 2025 to support potential submission
Dyne Therapeutics to Present at Upcoming Investor Conferences
07:30am, Monday, 03'rd Nov 2025
WALTHAM, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc . (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically drive
Why Dyne Therapeutics Stock Crushed the Market on Monday
06:17pm, Monday, 27'th Oct 2025
A peer is being acquired for a very high premium. The market is clearly thinking Dyne might be next on a potential buyer's shopping list.
This biotech's stock soared as investors look for the next buyout target
04:54pm, Monday, 27'th Oct 2025
Dyne Therapeutics' stock sees record rally, but one analyst says it could still climb a lot further, after a rival got bought out for a big premium.
Dyne Therapeutics, Inc. (NASDAQ:DYN) Given Average Rating of “Moderate Buy” by Brokerages
01:53am, Sunday, 26'th Oct 2025
Shares of Dyne Therapeutics, Inc. (NASDAQ: DYN - Get Free Report) have earned an average rating of "Moderate Buy" from the eighteen brokerages that are currently covering the company, Marketbeat Ratin
KLP Kapitalforvaltning AS Purchases 4,300 Shares of Dyne Therapeutics, Inc. $DYN
03:07am, Wednesday, 22'nd Oct 2025
KLP Kapitalforvaltning AS boosted its position in shares of Dyne Therapeutics, Inc. (NASDAQ: DYN) by 39.4% during the undefined quarter, according to its most recent Form 13F filing with the Securitie
Dyne: Accelerated Approval Established Endpoint Sets Stage For DM1 Data In Mid-2026
04:42pm, Wednesday, 08'th Oct 2025
Dyne Therapeutics received positive FDA feedback enabling a registrational cohort for z-basivarsen in DM1, with Accelerated Approval possible using vHOT as intermediate efficacy endpoint. DYN expects
- Robust improvement demonstrated across diverse set of clinical measures - - Patient-reported outcomes support clinical meaningfulness of improvements in function and strength - - Meaningful improvem
